“Forced myeloid differentiation by all-trans-retinoic acid (ATRA) effectively blocked acquisition of BCR-ABL mutations and resistance to the TKIs imatinib , nilotinib or dasatinib in our previously described in vitro models of acquired TKI resistance.”